ArticleTherapeutics and clinical risk management2017

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients.

Umberto Restelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.